National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 26792 [2013-10856]
Download as PDF
<![CDATA[
26792
Federal Register / Vol. 78, No. 89 / Wednesday, May 8, 2013 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
Ikpot (NHLBI), Denis O. Sviridov
(NHLBI), David O. Osei-Hwedieh
(NHLBI), Scott Turner (KineMed)
Publication: Osei-Hwedieh DO, et al.
Apolipoprotein mimetic peptides:
Mechanisms of action as antiatherogenic agents. Pharmacol Ther.
2011 Apr;130(1):83–91. [PMID
21172387]
Intellectual Property: HHS Reference
No. E–126–2011/0—US Application No.
61/480,986 filed 29 April 2011; PCT
Application No. PCT/US1235870 filed
30 April 2012
Licensing Contact: Lauren NguyenAntczak, Ph.D., J.D.; 301–435–4074;
lauren.nguyen-antczak@nih.gov
Collaborative Research Opportunity:
The NHLBI Lipoprotein Metabolism
Section is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize Hydrocarbon-stapled
Apolipoprotein Peptide Mimetics for
the Treatment of Cardiovascular
Diseases and Inflammation. For
collaboration opportunities, please
contact Denise Crooks, Ph.D. at
crooksd@nhlbi.nih.gov.
Parvovirus B19 Vaccine
Description of Technology: Parvovirus
B19 (B19V) infection causes fifth
disease, a disease characterized by
rashes to the face and other parts of the
body that primarily affects children.
However, adults can also develop fifth
disease and it can lead to more severe
conditions. Patients that are
immunocompromised, such as those
who are HIV infected, organ transplant
recipients, and cancer patients, can be
particularly susceptible to more severe
outcomes from B19V infection. Infection
can also cause anemia and in pregnant
women, it can lead to hydrops fetalis.
The subject technologies are
expression vectors for the production of
B19V VP1 and VP2 capsid proteins. Coexpression of the two proteins produce
empty virus-like particles (VLPs) that
can be used to develop a vaccine against
parvovirus B19 and a packaging system
for infectious B19V virus. Different
expression vectors have been developed
and optimized for expression in insects
cells and more recently in mammalian
cell lines such as 293, Cos7, Hela cells
and 293T cells.
Potential Commercial Applications:
Vaccine against parvovirus B19V.
Competitive Advantages: There is
currently no B19V vaccine on the
market.
Development Stage:
• Early-stage
• Pre-clinical
• Clinical
VerDate Mar<15>2010
17:56 May 07, 2013
Jkt 229001
• In vitro data available
• In vivo data available (animal)
• In vivo data available (human)
Inventors: Neal S. Young, Takashi
Shimada, Sachiko Kajigaya, Ning Zhi
(NHLBI)
Publications:
1. Bernstein DI, et al. Safety and
immunogenicity of a candidate
parvovirus B19 vaccine. Vaccine. 2011
Oct 6;29(43):7357–63. [PMID 21807052]
2. Zhi N, et al. Codon optimization of
human parvovirus B19 capsid genes
greatly increases their expression in
nonpermissive cells. J Virol. 2010
Dec;84(24):13059–62. [PMID 20943969]
Intellectual Property:
• HHS Reference No. E–286–1988/
2—U.S. Patent No. 5,916,563 issued 29
Jun 1999
• HHS Reference No. E–286–1988/
1—U.S. Patent No. 6,001,371 issued 14
Dec 1999; U.S. Patent No. 6,132,732
issued 17 Oct 2000
• HHS Reference No. E–266–2000/
0—U.S. Patent No. 6,558,676 issued 06
May 2003
• HHS Reference No. E–011–2010/
0—International PCT Appl. No. PCT/
US2011/024199 with national stage
filings in the U.S. and Europe
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018;
changke@mail.nih.gov
Collaborative Research Opportunity:
The National Heart, Lung, and Blood
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize the technology for
producing Parvovirus B19 vaccine. For
collaboration opportunities, please
contact Cecilia Pazman, Ph.D. at
pazmance@mail.nih.gov.
Dated May 2, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–10857 Filed 5–7–13; 8:45 am]
BILLING CODE 4140–01–P
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; R13 Conference.
Date: June 19, 2013.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: D. G. Patel, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 756, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK nGUDMAP
U01 Application Review.
Date: July 8, 2013.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Xiaodu Guo, Md, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 761, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: May 2, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–10856 Filed 5–7–13; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
E:\FR\FM\08MYN1.SGM
08MYN1
]]>Agencies
[Federal Register Volume 78, Number 89 (Wednesday, May 8, 2013)]
[Notices]
[Page 26792]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-10856]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; R13 Conference.
Date: June 19, 2013.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: D. G. Patel, Ph.D., Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 756,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; NIDDK nGUDMAP U01
Application Review.
Date: July 8, 2013.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW., Washington, DC 20015.
Contact Person: Xiaodu Guo, Md, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 761, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-4719, guox@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: May 2, 2013.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-10856 Filed 5-7-13; 8:45 am]
BILLING CODE 4140-01-P
